Brand Name(s):Ofev

Indication:Idiopathic Pulmonary Fibrosis (IPF).



Review Date:Feb-26

NICE TA379 states: Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:

* the person has a forced vital capacity (FVC) between 50% and 80% of predicted

* the company provides nintedanib with the discount agreed in the patient access scheme and

* treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12?month period.

NICE technology appraisal guidance [TA347]

Nintedanib, in combination with docetaxel, for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer. Full guidance available at:

July 2015